These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 16632079)

  • 21. Effects of aerobic exercise training in anemic cancer patients receiving darbepoetin alfa: a randomized controlled trial.
    Courneya KS; Jones LW; Peddle CJ; Sellar CM; Reiman T; Joy AA; Chua N; Tkachuk L; Mackey JR
    Oncologist; 2008 Sep; 13(9):1012-20. PubMed ID: 18779540
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessing symptom burden using the M. D. Anderson symptom inventory in patients with chemotherapy-induced anemia: results of a multicenter, open-label study (SURPASS) of patients treated with darbepoetin-alpha at a dose of 200 microg every 2 weeks.
    Gabrilove JL; Perez EA; Tomita DK; Rossi G; Cleeland CS
    Cancer; 2007 Oct; 110(7):1629-40. PubMed ID: 17694552
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Increased hemoglobin levels and improved quality-of-life assessments during epoetin alfa treatment in anemic cancer patients: results of a prospective, multicenter German trial.
    Reinhardt U; Tulusan A; Angermund R; Lutz H;
    Oncologist; 2005 Mar; 10(3):225-37. PubMed ID: 15793226
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Darbepoetin alfa administered every three weeks (Q3W) in anemic cancer patients receiving chemotherapy (CT).
    Martelli O; Garassino M; Sacchetta S; Caristo R; Zivi A; Cerbone L; Mancuso A
    Anticancer Res; 2008; 28(3B):1767-71. PubMed ID: 18630457
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study.
    Hedenus M; Adriansson M; San Miguel J; Kramer MH; Schipperus MR; Juvonen E; Taylor K; Belch A; Altés A; Martinelli G; Watson D; Matcham J; Rossi G; Littlewood TJ;
    Br J Haematol; 2003 Aug; 122(3):394-403. PubMed ID: 12877666
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact on health-related quality of life in kidney transplant recipients with late posttransplant anemia administered darbepoetin alfa: results from the STRATA study.
    Bloom RD; Bolin P; Gandra SR; Scarlata D; Petersen J
    Transplant Proc; 2011 Jun; 43(5):1593-600. PubMed ID: 21693239
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Early intervention with epoetin alfa during platinum-based chemotherapy: an analysis of the results of a multicenter, randomized, controlled trial based on initial hemoglobin level.
    Savonije JH; van Groeningen CJ; Wormhoudt LW; Giaccone G
    Oncologist; 2006 Feb; 11(2):206-16. PubMed ID: 16476841
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy.
    Crawford J; Cella D; Cleeland CS; Cremieux PY; Demetri GD; Sarokhan BJ; Slavin MB; Glaspy JA
    Cancer; 2002 Aug; 95(4):888-95. PubMed ID: 12209734
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fatigue- and health-related quality-of-life in anemic patients with lymphoma or multiple myeloma.
    Gascón P; Arranz R; Bargay J; Ramos F
    Support Care Cancer; 2018 Apr; 26(4):1253-1264. PubMed ID: 29116407
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of darbepoetin alfa administered every two weeks on hemoglobin and quality of life of patients receiving chemotherapy.
    Folloder J
    Oncol Nurs Forum; 2005 Jan; 32(1):81-91. PubMed ID: 15660146
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A randomized controlled trial of darbepoetin alfa administered as a fixed or weight-based dose using a front-loading schedule in patients with anemia who have nonmyeloid malignancies.
    Hesketh PJ; Arena F; Patel D; Austin M; D'Avirro P; Rossi G; Colowick A; Schwartzberg L; Bertoli LF; Cole JT; Demetri G; Dessypris E; Dobbs T; Eisenberg P; Fleischman R; Hall J; Hoffman PC; Laber DA; Leonard J; Lester EP; McCachren S; McMeekin S; Meza L; Miller DS; Nand S; Oliff I; Paroly W; Pawl L; Perez A; Raftopoulos H; Rigas J; Rowland K; Scullin DC; Tezcan H; Waples J; Ward J; Yee LK
    Cancer; 2004 Feb; 100(4):859-68. PubMed ID: 14770445
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Multicenter study of darbepoetin alfa in the treatment of anemia secondary to chronic renal insufficiency on dialysis].
    Martínez Castelao A; Reyes A; Valdés F; Otero A; López de Novales E; Pallardó L; Tabernero JM; Hernández Jaras J; Lladós F
    Nefrologia; 2003; 23(2):114-24. PubMed ID: 12778875
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical benefits of once-weekly epoetin alfa in anemic patients with colorectal cancer receiving chemotherapy.
    Chu E; Einhorn LH; Lefebvre P
    J Support Oncol; 2006 May; 4(5):243-50. PubMed ID: 16724648
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Randomized, double-blind, placebo-controlled trial of every-3-week darbepoetin alfa 300 micrograms for treatment of chemotherapy-induced anemia.
    Hernandez E; Ganly P; Charu V; Dibenedetto J; Tomita D; Lillie T; Taylor K;
    Curr Med Res Opin; 2009 Sep; 25(9):2109-20. PubMed ID: 19601709
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chronic anemia and fatigue in elderly patients: results of a randomized, double-blind, placebo-controlled, crossover exploratory study with epoetin alfa.
    Agnihotri P; Telfer M; Butt Z; Jella A; Cella D; Kozma CM; Ahuja M; Riaz S; Akamah J
    J Am Geriatr Soc; 2007 Oct; 55(10):1557-65. PubMed ID: 17697104
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A trial of subcutaneous administration of darbepoetin alfa once every other week for the treatment of anemia in peritoneal dialysis patients.
    Mahajan S; Boulton H; Gokal R
    J Nephrol; 2004; 17(5):687-92. PubMed ID: 15593036
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients.
    Nissenson AR; Swan SK; Lindberg JS; Soroka SD; Beatey R; Wang C; Picarello N; McDermott-Vitak A; Maroni BJ
    Am J Kidney Dis; 2002 Jul; 40(1):110-8. PubMed ID: 12087568
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical benefits of epoetin alfa (Eprex) 10,000 units subcutaneously thrice weekly in Thai cancer patients with anemia receiving chemotherapy.
    Voravud N; Sriuranpong V
    J Med Assoc Thai; 2005 May; 88(5):607-12. PubMed ID: 16149676
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The longitudinal relationship of hemoglobin, fatigue and quality of life in anemic cancer patients: results from five randomized clinical trials.
    Cella D; Kallich J; McDermott A; Xu X
    Ann Oncol; 2004 Jun; 15(6):979-86. PubMed ID: 15151958
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Standard of care for cancer-related anemia: improving hemoglobin levels and quality of life.
    Cortesi E; Gascón P; Henry D; Littlewood T; Milroy R; Pronzato P; Reinhardt U; Shasha D; Thatcher N; Wilkinson P
    Oncology; 2005; 68 Suppl 1():22-32. PubMed ID: 15855813
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.